Last reviewed · How we verify

combination of sumatriptan and naproxen

IRCCS San Raffaele Roma · Phase 2 active Small molecule

combination of sumatriptan and naproxen is a Small molecule drug developed by IRCCS San Raffaele Roma. It is currently in Phase 2 development.

At a glance

Generic namecombination of sumatriptan and naproxen
SponsorIRCCS San Raffaele Roma
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about combination of sumatriptan and naproxen

What is combination of sumatriptan and naproxen?

combination of sumatriptan and naproxen is a Small molecule drug developed by IRCCS San Raffaele Roma.

Who makes combination of sumatriptan and naproxen?

combination of sumatriptan and naproxen is developed by IRCCS San Raffaele Roma (see full IRCCS San Raffaele Roma pipeline at /company/irccs-san-raffaele-roma).

What development phase is combination of sumatriptan and naproxen in?

combination of sumatriptan and naproxen is in Phase 2.

Related